128 related articles for article (PubMed ID: 38242344)
41. ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis.
Peng DH; Ungewiss C; Tong P; Byers LA; Wang J; Canales JR; Villalobos PA; Uraoka N; Mino B; Behrens C; Wistuba II; Han RI; Wanna CA; Fahrenholtz M; Grande-Allen KJ; Creighton CJ; Gibbons DL
Oncogene; 2017 Apr; 36(14):1925-1938. PubMed ID: 27694892
[TBL] [Abstract][Full Text] [Related]
42. Comparative analysis of lysyl oxidase (like) family members in pulmonary fibrosis.
Aumiller V; Strobel B; Romeike M; Schuler M; Stierstorfer BE; Kreuz S
Sci Rep; 2017 Mar; 7(1):149. PubMed ID: 28273952
[TBL] [Abstract][Full Text] [Related]
43. LOXL2 promotes vasculogenic mimicry and tumour aggressiveness in hepatocellular carcinoma.
Shao B; Zhao X; Liu T; Zhang Y; Sun R; Dong X; Liu F; Zhao N; Zhang D; Wu L; Wang Y; Wang M; Meng J; Lin X; Sun B
J Cell Mol Med; 2019 Feb; 23(2):1363-1374. PubMed ID: 30506621
[TBL] [Abstract][Full Text] [Related]
44. Comprehensive Analysis on Prognosis and Immune Infiltration of Lysyl Oxidase Family Members in Pancreatic Adenocarcinoma With Experimental Verification.
Jiang C; Wang M; Yao W; Lv G; Liu X; Wang G
Front Mol Biosci; 2022; 9():778857. PubMed ID: 35433829
[No Abstract] [Full Text] [Related]
45. A tissue-specific variant of the human lysyl oxidase-like protein 3 (LOXL3) functions as an amine oxidase with substrate specificity.
Lee JE; Kim Y
J Biol Chem; 2006 Dec; 281(49):37282-90. PubMed ID: 17018530
[TBL] [Abstract][Full Text] [Related]
46. Lysyl oxidase-like 2 promotes stemness and enhances antitumor effects of gefitinib in head and neck cancer via IFIT1 and IFIT3.
Lu YJ; Deng YT; Ko HH; Peng HH; Lee HC; Kuo MY; Cheng SJ
Cancer Sci; 2023 Oct; 114(10):3957-3971. PubMed ID: 37496288
[TBL] [Abstract][Full Text] [Related]
47. LOXL2 small molecule inhibitor restrains malignant transformation of cervical cancer cells by repressing
Peng T; Lin S; Meng Y; Gao P; Wu P; Zhi W; Ding W; Cao C; Wu P
Cell Cycle; 2022 Sep; 21(17):1827-1841. PubMed ID: 35509127
[TBL] [Abstract][Full Text] [Related]
48. Identification of a novel lysyl oxidase-like 2 alternative splicing isoform, LOXL2 Δe13, in esophageal squamous cell carcinoma.
Lv GQ; Zou HY; Liao LD; Cao HH; Zeng FM; Wu BL; Xie JJ; Fang WK; Xu LY; Li EM
Biochem Cell Biol; 2014 Oct; 92(5):379-89. PubMed ID: 25275797
[TBL] [Abstract][Full Text] [Related]
49. LOXL2 upregulates hypoxia‑inducible factor‑1α signaling through Snail‑FBP1 axis in hepatocellular carcinoma cells.
Fan Z; Zheng W; Li H; Wu W; Liu X; Sun Z; Hu H; Du L; Jia Q; Liu Q
Oncol Rep; 2020 May; 43(5):1641-1649. PubMed ID: 32323822
[TBL] [Abstract][Full Text] [Related]
50. LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.
Chang J; Nicolau MM; Cox TR; Wetterskog D; Martens JW; Barker HE; Erler JT
Breast Cancer Res; 2013; 15(4):R67. PubMed ID: 23971878
[TBL] [Abstract][Full Text] [Related]
51. Escin Ia suppresses the metastasis of triple-negative breast cancer by inhibiting epithelial-mesenchymal transition via down-regulating LOXL2 expression.
Wang Y; Xu X; Zhao P; Tong B; Wei Z; Dai Y
Oncotarget; 2016 Apr; 7(17):23684-99. PubMed ID: 27008697
[TBL] [Abstract][Full Text] [Related]
52. LOXL2 serves as a prognostic biomarker for hepatocellular carcinoma by mediating immune infiltration and vasculogenic mimicry.
Zhao N; Chen C; Guo Y; Liu T; Che N; Zhang D; Liang X; Zhang Y; Zhao X
Dig Liver Dis; 2023 May; 55(5):661-672. PubMed ID: 36192339
[TBL] [Abstract][Full Text] [Related]
53. Exposure to desflurane anesthesia confers colorectal cancer cells metastatic capacity through deregulation of miR-34a/LOXL3.
Ren J; Wang X; Wei G; Meng Y
Eur J Cancer Prev; 2021 Mar; 30(2):143-153. PubMed ID: 32658033
[TBL] [Abstract][Full Text] [Related]
54. Emerging role of LOXL2 in the promotion of pancreas cancer metastasis.
Park JS; Lee JH; Lee YS; Kim JK; Dong SM; Yoon DS
Oncotarget; 2016 Jul; 7(27):42539-42552. PubMed ID: 27285767
[TBL] [Abstract][Full Text] [Related]
55. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma.
Wong CC; Tse AP; Huang YP; Zhu YT; Chiu DK; Lai RK; Au SL; Kai AK; Lee JM; Wei LL; Tsang FH; Lo RC; Shi J; Zheng YP; Wong CM; Ng IO
Hepatology; 2014 Nov; 60(5):1645-58. PubMed ID: 25048396
[TBL] [Abstract][Full Text] [Related]
56. LOXL2 reduces 5-FU sensitivity through the Hedgehog/BCL2 signaling pathway in colorectal cancer.
Qiu Z; Qiu S; Mao W; Lin W; Peng Q; Chang H
Exp Biol Med (Maywood); 2023 Mar; 248(6):457-468. PubMed ID: 36573458
[TBL] [Abstract][Full Text] [Related]
57. Lysyl oxidase-like-2 (LOXL2) is a major isoform in chondrocytes and is critically required for differentiation.
Iftikhar M; Hurtado P; Bais MV; Wigner N; Stephens DN; Gerstenfeld LC; Trackman PC
J Biol Chem; 2011 Jan; 286(2):909-18. PubMed ID: 21071451
[TBL] [Abstract][Full Text] [Related]
58. CCAAT enhancer binding protein α suppresses proliferation, metastasis, and epithelial-mesenchymal transition of ovarian cancer cells via suppressing the Wnt/β-catenin signaling.
Zhang LM; Li M; Tian CC; Wang TT; Mi SF
Neoplasma; 2021 May; 68(3):602-612. PubMed ID: 33780265
[TBL] [Abstract][Full Text] [Related]
59. MiR-504 inhibits cell proliferation and invasion by targeting LOXL2 in non small cell lung cancer.
Ye MF; Zhang JG; Guo TX; Pan XJ
Biomed Pharmacother; 2018 Jan; 97():1289-1295. PubMed ID: 29156517
[TBL] [Abstract][Full Text] [Related]
60. LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients.
Ahn SG; Dong SM; Oshima A; Kim WH; Lee HM; Lee SA; Kwon SH; Lee JH; Lee JM; Jeong J; Lee HD; Green JE
Breast Cancer Res Treat; 2013 Aug; 141(1):89-99. PubMed ID: 23933800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
